TY - JOUR
T1 - Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia
AU - Waanders, Esmé
AU - Gu, Zhaohui
AU - Dobson, Stephanie M
AU - Antić, Željko
AU - Crawford, Jeremy Chase
AU - Ma, Xiaotu
AU - Edmonson, Michael N
AU - Payne-Turner, Debbie
AU - van der Vorst, Maartje
AU - Jongmans, Marjolijn C J
AU - McGuire, Irina
AU - Zhou, Xin
AU - Wang, Jian
AU - Shi, Lei
AU - Pounds, Stanley
AU - Pei, Deqing
AU - Cheng, Cheng
AU - Song, Guangchun
AU - Fan, Yiping
AU - Shao, Ying
AU - Rusch, Michael
AU - McCastlain, Kelly
AU - Yu, Jiangyan
AU - van Boxtel, Ruben
AU - Blokzijl, Francis
AU - Iacobucci, Ilaria
AU - Roberts, Kathryn G
AU - Wen, Ji
AU - Wu, Gang
AU - Ma, Jing
AU - Easton, John
AU - Neale, Geoffrey
AU - Olsen, Scott R
AU - Nichols, Kim E
AU - Pui, Ching-Hon
AU - Zhang, Jinghui
AU - Evans, William E
AU - Relling, Mary V
AU - Yang, Jun J
AU - Thomas, Paul G
AU - Dick, John E
AU - Kuiper, Roland P
AU - Mullighan, Charles G
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research Inc. All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of childhood cancer-related death. Prior studies have shown clonal mutations at relapse often arise from relapse-fated subclones that exist at diagnosis. However, the genomic landscape, evolutionary trajectories, and mutational mechanisms driving relapse are incompletely understood. In an analysis of 92 cases of relapsed childhood ALL incorporating multimodal DNA and RNA sequencing, deep digital mutational tracking, and xenografting to formally define clonal structure, we identified 50 significant targets of mutation with distinct patterns of mutational acquisition or enrichment. CREBBP, NOTCH1, and RAS signaling mutations arose from diagnosis subclones, whereas variants in NCOR2, USH2A, and NT5C2 were exclusively observed at relapse. Evolutionary modeling and xenografting demonstrated that relapse-fated clones were minor (50%), major (27%), or multiclonal (18%) at diagnosis. Putative second leukemias, including those with lineage shift, were shown to most commonly represent relapse from an ancestral clone rather than a truly independent second primary leukemia. A subset of leukemias prone to repeated relapse exhibited hypermutation driven by at least three distinct mutational processes, resulting in heightened neoepitope burden and potential vulnerability to immunotherapy. Finally, relapse-driving sequence mutations were detected prior to relapse using droplet digital PCR at levels comparable with orthogonal approaches to monitor levels of measurable residual disease. These results provide a genomic framework to anticipate and circumvent relapse by earlier detection and targeting of relapse-fated clones.
AB - Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of childhood cancer-related death. Prior studies have shown clonal mutations at relapse often arise from relapse-fated subclones that exist at diagnosis. However, the genomic landscape, evolutionary trajectories, and mutational mechanisms driving relapse are incompletely understood. In an analysis of 92 cases of relapsed childhood ALL incorporating multimodal DNA and RNA sequencing, deep digital mutational tracking, and xenografting to formally define clonal structure, we identified 50 significant targets of mutation with distinct patterns of mutational acquisition or enrichment. CREBBP, NOTCH1, and RAS signaling mutations arose from diagnosis subclones, whereas variants in NCOR2, USH2A, and NT5C2 were exclusively observed at relapse. Evolutionary modeling and xenografting demonstrated that relapse-fated clones were minor (50%), major (27%), or multiclonal (18%) at diagnosis. Putative second leukemias, including those with lineage shift, were shown to most commonly represent relapse from an ancestral clone rather than a truly independent second primary leukemia. A subset of leukemias prone to repeated relapse exhibited hypermutation driven by at least three distinct mutational processes, resulting in heightened neoepitope burden and potential vulnerability to immunotherapy. Finally, relapse-driving sequence mutations were detected prior to relapse using droplet digital PCR at levels comparable with orthogonal approaches to monitor levels of measurable residual disease. These results provide a genomic framework to anticipate and circumvent relapse by earlier detection and targeting of relapse-fated clones.
U2 - 10.1158/0008-5472.BCD-19-0041
DO - 10.1158/0008-5472.BCD-19-0041
M3 - Article
C2 - 32793890
SN - 2643-3230
VL - 1
SP - 96
EP - 111
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 1
ER -